Atara Biotherapeutics: A Gift That Keeps On GivingSeeking AlphaIts focus is on the innovation allogenic T-cell immunotherapies (A-TCI) to service a vast number of cancers and autoimmune diseases (as depicted in figure 2). A-TCI functions quite similar … Continue reading
Medical News Today |
Cancer: Does sex affect the outcome of immunotherapy?
Medical News Today Immunotherapy — a type of treatment that aims to boost the body’s own defence mechanisms against disease — has been gaining ground lately as a more effective strategy against several cancers. It is typically used to treat cancer in its advanced … Patients’ sex may impact efficacy of immunotherapy in cancer treatmentMedical Xpress |
Telegraph.co.uk |
Better Responses to Immunotherapy in Men
Medscape The meta-analysis included 20 randomized controlled trials involving more than 11,351 patients with various solid tumors treated with immunotherapy. The drugs included ipilimumab (Yervoy, Bristol-Myers Squibb), tremelimumab (MedImmune, AstraZeneca), … The Lancet Oncology: Patients’ sex may impact efficacy of immunotherapy in cancer treatmentEurekAlert (press release) Is cutting-edge cancer therapy sexist? Study finds immunotherapy works half as well for womenTelegraph.co.uk Men Do Better than Women on Cancer ImmunotherapiesMedPage Today iNews –Globalnews.ca all 6 news articles » |
Telegraph.co.uk |
The Lancet Oncology: Patients’ sex may impact efficacy of …
EurekAlert (press release) A patient’s sex might impact on the efficacy of immunotherapy in cancer treatment, according to a new meta-analysis of 20 randomised trials in over 11000 … Is cutting-edge cancer therapy sexist? Study finds immunotherapy …Telegraph.co.uk Men Do Better than Women on Cancer Immunotherapies | Medpage …MedPage Today Cancer immunotherapy drugs may work better in men than womeniNews Globalnews.ca –The Times all 7 news articles » |
Reuters |
Roche immunotherapy combination increases lung cancer survival-study
Reuters (Reuters) – Roche’s immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage … |
Reuters |
Roche immunotherapy combination increases lung cancer survival-study
Reuters (Reuters) – Roche’s immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage … |